<DOC>
	<DOCNO>NCT02620046</DOCNO>
	<brief_summary>The purpose study obtain long term safety tolerability data vedolizumab subcutaneous ( vedolizumab SC ) participant ulcerative colitis ( UC ) Crohn 's disease ( CD ) .</brief_summary>
	<brief_title>Vedolizumab Subcutaneous Long-Term Open-Label Extension Study</brief_title>
	<detailed_description>The drug test study call vedolizumab subcutaneous ( vedolizumab SC ) . Vedolizumab SC test assess long-term safety effectiveness treat participant UC CD . This study look long-term side effect response/remission UC CD participant receive vedolizumab SC prior vedolizumab SC study . The study enroll 692 patient . All participant enrol study previously participate MLN0002SC-3027 MLN0002SC-3031 study . Participants complete Maintenance Period ( Week 52 ) previous study , achieve clinical response Week 6 achieve clinical response Week 14 received third vedolizumab IV infusion Week 6 previous study , receive open-label vedolizumab SC 108 mg , every 2 week ( Q2W ) . Participants withdraw early Maintenance Period previous study due disease worsen need rescue medication receive open-label vedolizumab SC 108 mg , every week ( QW ) . Participants experience treatment failure ( disease worsen need rescue medication current study dose escalate vedolizumab SC 108 mg QW . This multi-center trial conduct worldwide . Participation vedolizumab SC study continue vedolizumab SC become commercially available , participant withdraws study , sponsor decides close study . Participants make multiple visit clinic , plus final visit 18 week last dose study drug follow-up assessment . Participants also participate long-term safety follow-up , phone , 6 month last dose study drug .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Prior participation Study MLN0002SC3027 MLN0002SC3031 , , opinion investigator , tolerate study drug well . Early withdrawal Study MLN0002SC3027 MLN0002SC3031 must due treatment failure Maintenance Period . 1 . Surgical intervention IBD participation Study MLN0002SC3027 MLN0002SC3031 , time study . 2 . Chronic severe infection , , new , unstable , uncontrolled cardiovascular , pulmonary , hepatic , renal , gastrointestinal , genitourinary , hematological , coagulation , immunological , endocrine/metabolic , neurologic , oncologic , medical disorder develop participation prior vedolizumab study , opinion investigator , would confound study result compromise participant safety . 3 . Withdrawal Study MLN0002SC3027 MLN0002SC3031 due studydrug related adverse event ( AE ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>